What the company actually pays, and whether its own cash supports it.
What stands out
Pays more per share than it earned over the last twelve months
Dividends view
Yield
2.86%Below 5Y avg (4.29%)
Annual Rate
BRL 0.80Paid semi-annual
Payout Ratio
104.4%High
Payback Period
16.0 yr
Last Ex-Dividend
Aug 12, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
15.21BBRL
2.73B · vs all stocks (USD)
Updated Oct 25, 2026
Trailing P/E
24.03x
vs Diagnostics & Research peers
Updated Oct 25, 2026
Revenue (TTM)
8.79BBRL
1.58B · vs all stocks (USD)
Updated Oct 25, 2026
Profit Margin
8.01%
vs Diagnostics & Research peers
Updated Oct 25, 2026
52-Week Change
90.37%
vs all stocks
Updated Oct 25, 2026
Forward Annual Dividend Yield
2.86%
vs all stocks
Updated Oct 25, 2026
Market Capitalization
15.21BBRL
2.73B · vs all stocks (USD)
Updated Oct 25, 2026
Enterprise Value
18.80BBRL
3.38B · vs all stocks (USD)
Updated Oct 25, 2026
Trailing P/E
24.03x
vs Diagnostics & Research peers
Updated Oct 25, 2026
Forward P/E
16.58x
vs Diagnostics & Research peers
Updated Oct 25, 2026
PEG Ratio
1.98x
Updated Oct 25, 2026
Price to Sales (TTM)
1.72x
vs Diagnostics & Research peers
Updated Oct 25, 2026
Price to Book (MRQ)
3.04x
vs Diagnostics & Research peers
Updated Oct 25, 2026
Enterprise to Revenue
2.14x
vs Diagnostics & Research peers
Updated Oct 25, 2026
Enterprise to EBITDA
9.52x
vs Diagnostics & Research peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 7.66×.Updated Oct 25, 2026
Gross Margin
28.25%
vs Diagnostics & Research peers
Updated Oct 25, 2026
Profit Margin
8.01%
vs Diagnostics & Research peers
Updated Oct 25, 2026
Operating Margin
17.14%
vs Diagnostics & Research peers
Updated Oct 25, 2026
Return on Assets (TTM)
6.47%
vs Diagnostics & Research peers
Updated Oct 25, 2026
Return on Equity (TTM)
12.62%
vs Diagnostics & Research peers
Updated Oct 25, 2026
Revenue (TTM)
8.79BBRL
1.58B · vs all stocks (USD)
Updated Oct 25, 2026
Revenue per Share (TTM)
15.21BRLUpdated Oct 25, 2026
Quarterly Revenue Growth
14.40%
vs Diagnostics & Research peers
Updated Oct 25, 2026
Gross Profit (TTM)
2.38BBRL
427.50M · vs all stocks (USD)
Updated Oct 25, 2026
EBITDA (TTM)
2.45BBRL
440.94M · vs all stocks (USD)
Updated Oct 25, 2026
Net Income (TTM)
704.31MBRL
126.61M · vs all stocks (USD)
Updated Oct 25, 2026
Quarterly Earnings Growth (YoY)
45.70%
vs Diagnostics & Research peers
Updated Oct 25, 2026
Operating Cash Flow (TTM)
2.28BBRL
410.72M · vs all stocks (USD)
Updated Oct 25, 2026
Levered Free Cash Flow (TTM)
840.42MBRL
151.07M · vs all stocks (USD)
Updated Oct 25, 2026
Forward Annual Dividend Rate
0.8015BRLUpdated Oct 25, 2026
Forward Annual Dividend Yield
2.86%
vs all stocks
Updated Oct 25, 2026
Trailing Annual Dividend Rate
1.30BRLUpdated Oct 25, 2026
Trailing Annual Dividend Yield
4.65%
vs all stocks
Updated Oct 25, 2026
5-Year Average Dividend Yield
4.29%
vs all stocks
Updated Oct 25, 2026
Payout Ratio
104.36%
vs Diagnostics & Research peers
Provider-reported. Trailing Annual Dividend Rate ÷ Diluted EPS (TTM) on this page gives 112.05%.Updated Oct 25, 2026
Minority Interest (Equity)
94.93MBRLFY2025 · Dec 31, 2025
Revenue
8.29BBRLFY2025 · Dec 31, 2025
Cost of Goods Sold
6.09BBRLFY2025 · Dec 31, 2025
Gross Profit
2.21BBRLFY2025 · Dec 31, 2025
Operating Income
1.24BBRL
223.07M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
753.21MBRLFY2025 · Dec 31, 2025
Income Tax Expense
156.54MBRLFY2025 · Dec 31, 2025
Net Income
596.67MBRLFY2025 · Dec 31, 2025
EBIT
1.48BBRLFY2025 · Dec 31, 2025
EBITDA (Income Statement)
2.38BBRLFY2025 · Dec 31, 2025
Selling, General & Administrative
244.59MBRLFY2025 · Dec 31, 2025
Other Operating Expenses
30.74MBRLFY2025 · Dec 31, 2025
Non-operating Interest Income
324.74MBRLFY2025 · Dec 31, 2025
Non-operating Interest Expense
723.73MBRLFY2025 · Dec 31, 2025
EPS (Basic)
1.12BRLFY2025 · Dec 31, 2025
EPS (Diluted)
1.12BRLFY2025 · Dec 31, 2025
Basic Shares Outstanding
544.95MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
544.95MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
596.67MBRLFY2025 · Dec 31, 2025
Minority Interests (P&L)
16.16MBRLFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00BRLFY2025 · Dec 31, 2025
Operating Cash Flow
794.26MBRLFY2025 · Dec 31, 2025
Free Cash Flow
288.19MBRLFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
21.77MBRLFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
596.67MBRLFY2025 · Dec 31, 2025
Stock-based Compensation
29.05MBRLFY2025 · Dec 31, 2025
Other Non-cash Items
531.97MBRLFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-255.99MBRLFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-107.44MBRLFY2025 · Dec 31, 2025
Capital Expenditures
-506.07MBRLFY2025 · Dec 31, 2025
Net Acquisitions
-180.99MBRLFY2025 · Dec 31, 2025
Net Investing Cash Flow
-687.06MBRLFY2025 · Dec 31, 2025
Long-term Debt Issuance
116.13MBRLFY2025 · Dec 31, 2025
Long-term Debt Payments
-221.95MBRLFY2025 · Dec 31, 2025
Common Stock Repurchase
0.00BRLFY2025 · Dec 31, 2025
Common Dividends Paid
-513.05MBRLFY2025 · Dec 31, 2025
Other Financing Charges
-3.71MBRLFY2025 · Dec 31, 2025
Net Financing Cash Flow
-622.60MBRLFY2025 · Dec 31, 2025
Shares Outstanding
543.63MSharesUpdated Oct 25, 2026
Float Shares
241.71MSharesUpdated Oct 25, 2026
% Held by Insiders
55.28%
vs all stocks
Updated Oct 25, 2026
% Held by Institutions
27.50%
vs all stocks
Updated Oct 25, 2026
Total Cash (MRQ)
1.90BBRL
341.39M · vs all stocks (USD)
Updated Oct 25, 2026
Total Cash per Share (MRQ)
3.48BRLUpdated Oct 25, 2026
Total Debt (MRQ)
5.41BBRL
972.32M · vs all stocks (USD)
Updated Oct 25, 2026
Total Debt to Equity (MRQ)
0.9802x
vs Diagnostics & Research peers
Updated Oct 25, 2026
Current Ratio (MRQ)
1.86x
vs Diagnostics & Research peers
Updated Oct 25, 2026
Book Value per Share (MRQ)
9.18BRLUpdated Oct 25, 2026
Total Assets
13.22BBRL
2.38B · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
4.42BBRLFY2025 · Dec 31, 2025
Total Liabilities
8.12BBRLFY2025 · Dec 31, 2025
Total Non-current Assets
8.80BBRLFY2025 · Dec 31, 2025
Total Non-current Liabilities
5.88BBRLFY2025 · Dec 31, 2025
Total Current Liabilities
2.25BBRLFY2025 · Dec 31, 2025
Cash & Cash Equivalents
21.77MBRLFY2025 · Dec 31, 2025
Other Short-term Investments
2.14BBRLFY2025 · Dec 31, 2025
Accounts Receivable
1.75BBRLFY2025 · Dec 31, 2025
Inventory
180.70MBRLFY2025 · Dec 31, 2025
Accounts Payable
800.13MBRLFY2025 · Dec 31, 2025
Short-term Debt
550.84MBRLFY2025 · Dec 31, 2025
Other Current Liabilities
2.17MBRLFY2025 · Dec 31, 2025
Long-term Debt
4.72BBRLFY2025 · Dec 31, 2025
Other Non-current Liabilities
71.00MBRLFY2025 · Dec 31, 2025
Common Stock (Book)
2.74BBRLFY2025 · Dec 31, 2025
Retained Earnings
332.45MBRLFY2025 · Dec 31, 2025
Total Shareholders' Equity
5.10BBRL
916.11M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
35.56MBRLFY2025 · Dec 31, 2025
52-Week Low
13.90BRLUpdated Oct 25, 2026
52-Week High
28.65BRLUpdated Oct 25, 2026
52-Week Change
90.37%
vs all stocks
Updated Oct 25, 2026
50-Day MA
22.25BRLUpdated Oct 25, 2026
200-Day MA
17.75BRLUpdated Oct 25, 2026
Avg 10-Day Volume
6.25MSharesUpdated Oct 25, 2026
Avg 30-Day Volume
5.30MSharesUpdated Oct 25, 2026
Diluted EPS (TTM)
1.16BRLUpdated Oct 25, 2026
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Pays more per share than it earned over the last twelve monthsSignificant
Payout Ratio: 1.04Dividend per Share: 1.30Earnings per Share: 1.16